We are live on ! Find out more
BCM

Boone Capital Management Portfolio holdings

AUM $326M
1-Year Est. Return 86.31%
This Fund
S&P 500
This Quarter Est. Return
-4.97%
1 Year Est. Return
+86.31%
3 Year Est. Return
+255.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$383M
AUM Growth
-$111M
Cap. Flow
-$77.1M
Cap. Flow %
-20.11%
Top 10 Hldgs %
75.36%
Holding
24
New
3
Increased
6
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
IQV icon
IQVIA
IQV
+$21.5M
2
CERT icon
Certara
CERT
+$11.8M
3
CRL icon
Charles River Laboratories
CRL
+$10.9M
4
DHR icon
Danaher
DHR
+$10.2M
5
GMED icon
Globus Medical
GMED
+$6.42M

Top Sells

Rank Stock Value
1
ENOV icon
Enovis
ENOV
+$35.1M
2
BIO icon
Bio-Rad Laboratories Class A
BIO
+$25M
3
MLAB icon
Mesa Laboratories
MLAB
+$14.6M
4
VTRS icon
Viatris
VTRS
+$13.5M
5
TARS icon
Tarsus Pharmaceuticals
TARS
+$13.2M

Sector Composition

Rank Sector Weight
1 Healthcare 83.61%
2 Financials 12.4%
3 Materials 3.99%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNM icon
1
Unum
UNM
$13.6B
$47.6M 12.4%
930,545
-94,482
-9% -$4.89M
GMED icon
2
Globus Medical
GMED
$10.7B
$43.6M 11.38%
637,315
+107,490
+20% +$6.42M
CI icon
3
Cigna
CI
$74.7B
$43.6M 11.37%
131,926
– –
MOH icon
4
Molina Healthcare
MOH
$10.2B
$29.5M 7.68%
99,094
+13,378
+16% +$4.54M
DHR icon
5
Danaher
DHR
$138B
$26.6M 6.93%
106,360
+40,549
+62% +$10.2M
BAX icon
6
Baxter International
BAX
$13.5B
$24.1M 6.29%
721,278
+23,321
+3% +$860K
IQV icon
7
IQVIA
IQV
$38.6B
$20M 5.22%
+94,734
New +$21.5M
AMPH icon
8
Amphastar Pharmaceuticals
AMPH
$873M
$19.8M 5.17%
495,089
-111,599
-18% -$4.62M
MIRM icon
9
Mirum Pharmaceuticals
MIRM
$6.63B
$17.9M 4.67%
523,679
+71,781
+16% +$1.88M
PNTG icon
10
Pennant Group
PNTG
$1.41B
$16.2M 4.23%
699,966
+135,774
+24% +$2.98M
BERY
11
DELISTED
Berry Global Group, Inc.
BERY
$15.3M 3.99%
282,824
-207,336
-42% -$11.3M
IDYA icon
12
IDEAYA Biosciences
IDYA
$3.42B
$14.8M 3.86%
422,049
-109,918
-21% -$4.35M
OFIX icon
13
Orthofix Medical
OFIX
$473M
$10.3M 2.68%
775,368
-199,134
-20% -$2.73M
CRL icon
14
Charles River Laboratories
CRL
$11.2B
$9.98M 2.6%
+48,288
New +$10.9M
CERT icon
15
Certara
CERT
$1.23B
$9.96M 2.6%
+718,983
New +$11.8M
XENE icon
16
Xenon Pharmaceuticals
XENE
$6.1B
$9.77M 2.55%
250,460
-40,943
-14% -$1.64M
VKTX icon
17
Viking Therapeutics
VKTX
$3.73B
$9.26M 2.42%
174,766
-135,696
-44% -$8.89M
HCSG icon
18
Healthcare Services Group
HCSG
$1.59B
$9.24M 2.41%
873,018
-53,437
-6% -$593K
TARS icon
19
Tarsus Pharmaceuticals
TARS
$2.56B
$5.87M 1.53%
216,047
-393,057
-65% -$13.2M
BIO icon
20
Bio-Rad Laboratories Class A
BIO
$8.71B
– –
-72,344
Closed -$25M
ENOV icon
21
Enovis
ENOV
$1.68B
– –
-562,739
Closed -$35.1M
MLAB icon
22
Mesa Laboratories
MLAB
$555M
– –
-133,394
Closed -$14.6M
QTRX icon
23
Quanterix
QTRX
$164M
– –
-330,151
Closed -$7.78M
VTRS icon
24
Viatris
VTRS
$20.5B
– –
-1,133,591
Closed -$13.5M

Similar funds

ISFAN
Investor's Fiduciary Advisor Network Snoqualmie, Washington $326M AUM 19.7% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM
AFA
Alpha Financial Advisors Charlotte, North Carolina $326M AUM 15.49% 1-Year Est. Return
ECH
ER Collective Holdings Washington, District of Columbia $326M AUM
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
MVM
Menlo Ventures Management Menlo Park, California $327M AUM
CCG
Ceeto Capital Group Coral Gables, Florida $326M AUM 24.81% 1-Year Est. Return
TC
TFR Capital Plano, Texas $326M AUM 24.24% 1-Year Est. Return

Boone Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Boone Capital Management held 24 positions worth $383M, down 22% from $494M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Boone Capital Management withdrew a net $77.1M in Q2 2024, closing 5 positions and reducing 9 holdings. Its most notable exit was Enovis, an estimated $35.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 80% a quarter earlier, followed by Financials and Materials.

Against the trend, Boone Capital Management opened a new position in IQVIA worth $20M.

  • Boone Capital Management's largest Q2 2024 buy was IQVIA: 94,734 shares worth $20M.
  • Boone Capital Management added most to Danaher in Q2 2024, an estimated $10.2M increase.
  • Boone Capital Management's biggest Q2 2024 reduction was Tarsus Pharmaceuticals, cutting an estimated $13.2M.
  • Boone Capital Management fully exited Enovis in Q2 2024, selling an estimated $35.1M.
  • Boone Capital Management's ten largest holdings make up 75% of its $383M portfolio in Q2 2024.
  • Boone Capital Management opened 3 new positions and closed 5 in Q2 2024.
  • Boone Capital Management's portfolio value fell 22% quarter-over-quarter to $383M.

Based on Boone Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.